← Back to all trials
Recruiting
NCT05597566
Predictive Effect of Neuroinflammatory Factors of the MECT in Treatment of Senile Depression
Conditions: Major Depression Disorder
Sex: All
Ages: 60 Years – 85 Years
Enrollment: 72
Sponsor: Qinge Zhang
Location: China
Summary
To compare the correlation between the clinical efficacy of MECT treatment and baseline, 3 times, 8 times of treatment, 1 week after treatment, and 2 weeks after treatment in patients with depression and suicidal ideation.
The prediction effect of -1β and IL-6 levels and level changes on the efficacy of MECT in the treatment of suicidal ideation in elderly patients with depression, and provide a theoretical basis for further research on the mechanism of MECT in the treatment of elderly depression with suicidal ideation.
Eligibility Criteria
Inclusion Criteria:Provide written informed consent; Age 60 to 85 years old, including 60 and 85 years old;Meet the diagnostic criteria for single or recurrent major depressive disorder in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition);Currently in the acute phase, with a total score of 17-item Hamilton Depression Rating Scale (HDRS-17) ≥ 24 at baseline;History of suicide attempt in this depressive episode; Rating Scale (SIOSS)≥12 points;Exclusion Criteria:Patients with a history of epilepsy or coronary heart disease or other serious unstable physical diseases;Patients with acute inflammatory infection or chronic inflammatory disease; Patients in the past 1 month Participated in another interventional clinical study;Past or current diagnosis of the following psychiatric diseases by DSM-IV: organic mental disorder, Alzheimer's disease, secondary dementia due to other causes, mental illness Schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder, unspecified mental illness, and patients with a history of drug abuse, including alcohol and active drug abuse in the past 12 months, except for nicotine;Severe aphasia , visual and hearing impairment, etc. who cannot complete the scale evaluation;Those who have contraindications to MECT treatment;Those who are pregnant, lactating women or planning to become pregnant; Those who are allergic to atropine, propofol, and succinylcholine chloride.
Source: ClinicalTrials.gov (NCT05597566). StuddyBuddy aggregates publicly available trial information.